ベルギー - オランダ語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - topotecanhydrochloride 1,0865 mg/ml - eq. topotecan 1 mg/ml - concentraat voor oplossing voor infusie - 1 mg/ml - topotecanhydrochloride - topotecan

カナダ - フランス語 - Health Canada

accord healthcare inc - topotécane (chlorhydrate de topotécan) - solution - 1mg - topotécane (chlorhydrate de topotécan) 1mg - antineoplastic agents

フィンランド - フィンランド語 - Fimea (Suomen lääkevirasto)

ebewe pharma ges.m.b.h. nfg.kg - topotecan hydrochloride - infuusiokonsentraatti, liuosta varten - 1 mg/ml - topotekaani

フィンランド - フィンランド語 - Fimea (Suomen lääkevirasto)

accord healthcare b.v. - topotecan hydrochloride - infuusiokonsentraatti, liuosta varten - 1 mg/ml - topotekaani

ベルギー - ドイツ語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare - topotecan hydrochloride - konzentrat zur herstellung einer infusionslösung - 1 mg/ml - topotecan hydrochloride - topotecan

ベルギー - ドイツ語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare - topotecan hydrochloride - konzentrat zur herstellung einer infusionslösung - 1 mg/ml - topotecan hydrochloride - topotecan

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

accord healthcare, inc. - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (sclc) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. topotecan hydrochloride for injection, in combination with cisplatin, is indicated for the treatment of patients with stage iv-b, recurrent, or persistent cervical cancer not amenable to curative treatment. topotecan hydrochloride for injection is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. reactions have included anaphylactoid reactions [see adverse reactions ( 6.2)] . risk summary based on animal data and its mechanism of action, topotecan hydrochloride for injection can

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

cipla usa inc. - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (sclc) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of patients with stage iv-b, recurrent, or persistent cervical cancer of the cervix not amenable to curative treatment. topotecan hydrochloride for injection is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. reactions have included anaphylactoid reactions [see adverse reactions (6.2)]. risk summary based on animal data and its mechanism of action, topotecan hydrochloride for injection can cause fetal harm when administe

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

actavis pharma, inc. - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (sclc) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. topotecan hydrochloride for injection, in combination with cisplatin, is indicated for the treatment of patients with stage iv-b, recurrent, or persistent cervical cancer not amenable to curative treatment. topotecan hydrochloride is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. reactions have included anaphylactoid reactions [see adverse reactions (6.2)]. risk summary based on animal data and its mechanism of action, topotecan hydrochloride can cause fetal harm when administered to a pregnant woman. there are no av

ベルギー - フランス語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - chlorhydrate de topotécan 1,0865 mg/ml - eq. topotécan 1 mg/ml - solution à diluer pour perfusion - 1 mg/ml - chlorhydrate de topotécan - topotecan